Assessment of Wall Thickness in Hypertrophic Cardiomyopathy

Overview

About this study

Assessment of wall thickness in hypertrophic cardiomyopathy (HCM) is of diagnostic and prognostic importance given its known association with sudden cardiac death. However, data regarding comparison of imaging modalities for this key measurement is lacking. This study seeks to compare assessment of maximum wall thickness between clinically indicated echocardiography (with and without contrast) and clinically indicated cardiac magnetic resonance imaging.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Clinically and echocardiographically defined hypertrophic cardiomyopathy.
Clinically indicated transthoracic echocardiography as part of the medical evaluation.
No contradiction to administration of ultrasonic echocardiography contrast.
Planned clinically indicated cardiac magnetic resonance imaging as part of medical evaluation.
No contraindication to cardiac magnetic resonance imaging (such as cochlear implants, central nervous system aneurysm clips and other implanted medical devices).
Age 18 years and older.

Exclusion Criteria:

Individuals < 18 years old.
Insufficient image quality for determination of maximal wall thickness.

Eligibility last updated 5/24/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Patricia Pellikka, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Patricia Pellikka, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials